Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutiki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Newport Huntington Medical Group /ID# 272764, Huntington Beach, California +21 locations
Conditions: Psoriatic Arthritis
Register for Updates
Tracking Results of Ablations to Combat AF Registry Generation 2
NCT05111015
Recruiting
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct concomitant open heart and/or hybrid ablation, and management of the Left Atrial Appendage concomitant to a cardiac ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Huntsville Hospital, Huntsville, Alabama +22 locations
Conditions: Atrial Fibrillation
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961
Recruiting
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Dermatology Research Associate, Los Angeles, California +33 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666
Recruiting
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/11/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +30 locations
Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Register for Updates
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT06449001
Recruiting
The primary objective of this study is to evaluate efficacy of danicopan as add-on treatment to ravulizumab or eculizumab as assessed by hemoglobin (Hgb) change from Baseline at Week 12 in pediatric participants with paroxysmal nocturnal hemoglobinuria (PNH) and clinically significant extravascular hemolysis (CS-EVH).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/11/2025
Locations: Research Site, Saskatoon, Saskatchewan +2 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Register for Updates
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Recruiting
This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 patients will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona +39 locations
Conditions: VEXAS, VEXAS Syndrome
Register for Updates
International CRDS Registry
NCT06508164
Recruiting
Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.
Gender:
ALL
Ages:
All
Trial Updated:
08/11/2025
Locations: University of California, San Francisco, California +8 locations
Conditions: Calcium Release Deficiency Syndrome
Register for Updates
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461
Recruiting
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual immunotherapy treatment called Immune Checkpoint Blockade (ICB)? FMT treatment changes the bacteria in your gut called the microbiome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario +7 locations
Conditions: Melanoma
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +219 locations
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/11/2025
Locations: Research Site, Birmingham, Alabama +862 locations
Conditions: Heart Failure
Register for Updates
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
NCT06391242
Recruiting
This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most affected by cancer, while keeping the radiation beams away from the healthy parts of the body that surround the cancer) better for pain relief than the standard treatment of conventional radiation therapy or CRT (a form of radiation therapy which delivers radiation to the pain... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Kingston Health Sciences Centre, Kingston, Ontario +3 locations
Conditions: Cancer Metastatic
Register for Updates
Adding Chondrus Crispus Seaweeds to a Meal: Effect on Sensory Perception, Physical Comfort, Satiety and Food Intake
NCT07127393
Recruiting
The study investigates the sensory characteristics, consumer perception and the effect on satiety and food intake of the meal with added Chondrus crispus seaweed produced by Acadian Seaplants in Atlantic Canada.
Gender:
MALE
Ages:
Between 19 years and 35 years
Trial Updated:
08/11/2025
Locations: Appetite Lab, Halifax, Nova Scotia
Conditions: Satiety and Food Intake, Sensory Evaluation, Physical Comfort
Register for Updates